A 2-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy, Eisa